Questcor (QCOR -21.8%) has now lost over a fifth of its value thanks to a harsh Citron Research...

|By:, SA News Editor

Questcor (QCOR -21.8%) has now lost over a fifth of its value thanks to a harsh Citron Research report. Piper (Outperform) defends the company by arguing generic drugs aren't a risk to Acthar sales, and would require a 30-month stay in the event of a filing. However, the generic threat was just one of several issues raised by Citron.